Axalimogene filolisbac

N/A

Report date: 2024/08/01 20:00:04

Base Information

Drug NameAxalimogene filolisbac
Drug Alias NameCervical cancer vaccine菲罗阿莫基Listeria cancer vaccine菲-阿萨利莫近axalimogenum filolisbacum +[21] 
ClassificationVaccines > Development/production technology > Live attenuated vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulantsProtein E7 inhibitors
TargetsProtein E7
Therapy Area/IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungOropharyngeal Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUkraine +[14] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAyala Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOS Therapies IncAyala Pharmaceuticals IncBrown University
Active IndicationsN/A
Inactive IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungOropharyngeal Neoplasms +[10] 

Other Information

ATC CodeN/A
Related LinksN/A